Jeremy Tchack
Overview
Explore the profile of Jeremy Tchack including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
147
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kshattry S, White M, Tchack J, Laskin W, Kunz P
Chest
. 2023 Jan;
163(1):e23-e29.
PMID: 36628681
A 46-year-old previously healthy woman presented with dyspnea, fatigue, and diarrhea. She had been experiencing these symptoms for > 1 year, but they had worsened in the few weeks prior...
2.
Robinson E, Rosenbaum B, Zhang Y, Rogers R, Tchack J, Berman R, et al.
J Surg Oncol
. 2018 Jun;
118(1):150-156.
PMID: 29878361
Background: Patients with thick primary melanomas (≥4 mm) have highly variable survival outcomes. Cell proliferation marker Ki-67 has been identified as promising biomarker in thick melanoma but has not been...
3.
Lattanzi M, Han J, Moran U, Utter K, Tchack J, Sabado R, et al.
J Immunother Cancer
. 2018 May;
6(1):38.
PMID: 29773080
Background: Cancer-testis antigen NY-ESO-1 is a highly immunogenic melanoma antigen which has been incorporated into adjuvant vaccine clinical trials. Three such early-phase trials were conducted at our center among patients...
4.
Gowen M, Giles K, Simpson D, Tchack J, Zhou H, Moran U, et al.
J Transl Med
. 2018 Apr;
16(1):82.
PMID: 29606147
Background: Immune checkpoint inhibitors (anti-CTLA-4, anti-PD-1, or the combination) enhance anti-tumor immune responses, yielding durable clinical benefit in several cancer types, including melanoma. However, a subset of patients experience immune-related...
5.
Goldman C, Tchack J, Robinson E, Han S, Moran U, Polsky D, et al.
Oncology
. 2017 Jun;
93(3):164-176.
PMID: 28601879
Objectives: Since 2011, metastatic melanoma treatment has evolved with commercial approval of BRAF- and MEK-targeted therapy and CTLA-4- and PD-1-blocking antibodies (immune checkpoint inhibitors, ICI). While novel therapies have demonstrated...
6.
Weiss S, Han S, Lui K, Tchack J, Shapiro R, Berman R, et al.
Hum Pathol
. 2017 Apr;
63:222.
PMID: 28449825
No abstract available.
7.
Weiss S, Han J, Darvishian F, Tchack J, Han S, Malecek K, et al.
J Transl Med
. 2016 Oct;
14(1):299.
PMID: 27760559
Background: Age has been reported as an independent prognostic factor for melanoma-specific survival (MSS). We tested the hypothesis that age impacts the host anti-tumor immune response, accounting for age-specific survival...
8.
Weiss S, Han S, Lui K, Tchack J, Shapiro R, Berman R, et al.
Hum Pathol
. 2016 Jul;
57:116-125.
PMID: 27473267
Tumor-infiltrating lymphocytes (TILs) in primary melanomas are thought to represent the host antitumor immune response, but controversy exists over whether TILs offer independent prognostication of survival. We studied a cohort...